Status:
COMPLETED
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
Lead Sponsor:
Pfizer
Conditions:
Covid-19
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir...
Eligibility Criteria
Inclusion
- Confirmed COVID-19 infection during the study observation period
- Nirmatrelvir, ritonavir written prescription
Exclusion
- None
Key Trial Info
Start Date :
October 17 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 9 2024
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06016556
Start Date
October 17 2023
End Date
April 9 2024
Last Update
June 5 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
King Faisal Specialist Hospital & research center - Jeddah
Jeddah, Saudi Arabia, 21499
2
King Abdulaziz Medical City
Riyadh, Saudi Arabia, 11426
3
King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia